TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men
PHOENIX, Aug. 3 /PRNewswire-USNewswire/ -- The Phoenix-based Kronos Longevity Research Institute (KLRI) has published two new publications on hormone therapies and their effects on reducing the risks of cardiovascular disease in older adults.
Cardiovascular disease caused by ...
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
SEATTLE, June 22 /PRNewswire-FirstCall/ --
Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups
Additional Clinical Studies Also Highlighted at Pan ...
Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
FRANKLIN LAKES, N.J., June 8, /PRNewswire-FirstCall/ -- Research presented at the American Diabetes Association's 69th Scientific Sessions points to increased risk for people with diabetes associated with two widely used drug classes; while another study shed new light on a different class of drug...
Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
BOSTON, May 23 /PRNewswire/ -- Amid all the speculation over what course the Swine Flu epidemic will take, Boston-based biotech firm Replikins Ltd. ( www.replikins.com ) last week analyzed the most recent peptide genomic sequence data available and determined that the infectivity of the H1N1 vir...
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare is...
Young Smokers Increase Risk for Multiple Sclerosis
SEATTLE, Feb. 23 /PRNewswire-USNewswire/ -- People who start smoking before age 17 may increase
their risk for developing multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May...
Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
ANN ARBOR, Mich., Jan. 16 /PRNewswire/ -- Use of prescription sleep aids
nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a
study released today by the Healthcare business of Thomson Reuters.
During the study period, the average length of time sleep aids were...
FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
PHILADELPHIA, Nov. 20 /PRNewswire-FirstCall/ --GlaxoSmithKline (NYSE: GSK ) today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immu...
MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
REHOVOT, Israel and JERSEY CITY, New Jersey, September 18
/PRNewswire-FirstCall/ -- - A Collaborative Study by Scientists at the
Weizmann Institute of Science and Scientists at Sheba Medical Center, With
the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451
Inhibited Growth ...
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
- New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 vs. 1.9 months with placebo
- One quarter of patients in trial remained progression-free beyond ten months of treatment
- RAD001 is first drug to show significa...
August 2008 Mayo Clinic Women's HealthSource Highlights Avoiding Blood Pressure Increase at Menopause, Healthful Benefits of Dark Chocolate and Scheduling a Colorectal Exam
ROCHESTER, Minn., Aug. 6 /PRNewswire-USNewswire/ -- Here are highlights
from the August issue of Mayo Clinic Women's HealthSource. You may cite
this publication as often as you wish. Mayo Clinic Women's HealthSource
attribution is required. Reprinting is allowed for a fee. Include the
BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
- Second instance where survival increase
is observed in advanced non-small
cell lung cancer patients receiving Tavocept in conjunction with standard chemotherapy - Median survival increase
of 6.5 months seen for patients with adenocarcinoma, the most comm...
DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
REYKJAVIK, Iceland, June 30 /PRNewswire-FirstCall/ -- deCODE genetics
(Nasdaq: DCGN ) today announced positive topline results from its latest
clinical pharmacology study of DG041, the company's first-in-class
antagonist of the EP3 receptor for prostaglandin E2, developed as a
Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology
CEDAR KNOLLS, N.J., April 16 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that additional
preclinical in vivo studies using dogs further demonstrate that its
proprietary eligen(R) technology enhances the absorption of oral B12. These
data confirm in a...
Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
'On Track' Initiative Provides Broader Access to FOSRENOL(R) and Resources for Enhanced Hyperphosphatemia Management
PHILADELPHIA, April 3, 2008 /PRNewswire/ -- Shire Pharmaceuticals, the
global biopharmaceutical company, today announced the launch of On Track,
an innovative progr...
New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinson's Clinical Trials
NEW YORK, March 19 /PRNewswire-USNewswire/ -- As part of its ongoing
efforts to develop research tools that can speed the availability of
life-transforming treatments for Parkinson's disease, The Michael J. Fox
Foundation announced the launch of its Web-based Clinical Assessment
Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
PHILADELPHIA, Feb. 1 /PRNewswire-USNewswire/ -- Obese teenagers who
succeeded in losing weight in a year-long medically supervised weight
control program also saw their bone mineral content increase
period, say researchers from The Children's Hospital of Philadelphia. The
Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
WASHINGTON, Nov. 1 /PRNewswire-USNewswire/ -- Multiple myeloma is one
of the most common and devastating bone marrow cancers in the U.S., but
survival rates have risen dramatically over the past decade. Recent
analyses suggest that this trend may be attributed to new types of drugs
REACH Registry Demonstrates That Multiple Arterial Disease
Locations Sharply Increase the Risk of Major CV Events in
Outpatients With Atherothrombosis
- The Reduction of Atherothrombosis for Continued Health
- Registry 1-Year Results
PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-year
results paper published today in the Journal of the American
Medical Association (JAMA) show that outpatients with
atherothrombosis have a s...
Abraxis BioScience Presents Data from Pre-Clinical Study That
Provide Evidence for Chemotherapy-Induced Angiogenesis and
Rationale for Combining nab-Paclitaxel (Abraxane) with
Anti-Angiogenic Agents to Increase Tumor Response
LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,
Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical
company, discussed results from two pre-clinical studies that
provide evidence for chemotherapy induced angiogenesis and
rationale for combining nab-paclitaxel (ABRAXANE(R) f...
Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in
LUCCA, ITALY, May 14, 2007-Acceleron Pharma, Inc., a
biopharmaceutical company developing therapeutics for the treatment
of musculoskeletal, metabolic and cancer-related diseases, today
announced results of a preclinical study with ACE-031 that
demonstrated the ability of the compound to inc...
Auxilium Announces New Data That Show Total Testosterone Blood
Levels Increase Significantly Following Switch from AndroGel(R) to
MALVERN, Pa., May 22, 2007 /PRNewswire-FirstCall/ -- Auxilium
Pharmaceuticals, Inc. today announced that new data show
improvements in symptoms of decreased libido, energy levels and
erectile function in 76 percent of hypogonadal men after switching
brands of testosterone replacement gel therapy. ...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...ing Expenses" section below, offset in part, by an increase
in revenue recognized in 2009 from Isis' corporate...lion in the same periods of 2008. The substantial increase
in Isis' revenue is primarily due to an increase
in revenue from the Company's collaboration with G...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
... developing tissues and appear to play an important role in regulating bone remodeling in adults. While both peptides have demonstrated the ability to increase
bone mineral density and bone strength in humans, PTHrP and its analogs do not stimulate adverse bone resorption and hypercalcemia to the same extent ...
NewCardio Announces Master Services Agreement With Dedicated Phase I
...Cardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase
the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to ...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
...g, naloxone. Nektar's technology has been shown to increase
oral bioavailability and inhibit penetration acros...ther assets 1,284 (6,026)
(decrease) in accounts payable (5,513) (1,727)
(decrease) in accrued compensation (4,687) (3...
Study Shows Brain Fitness can Save Medicare Billions
...e than 30 articles in leading science and medical journals show that in randomized controlled trials the company's patented technologies significantly increase
processing speed, improve memory and attention and enhance quality of life. Posit Science has received grants from the National Institutes of Health a...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
...the risk for relapse in patients can substantially increase
as a result of non-adherence.(2) Research shows th...chance that it will become permanent is thought to increase
with the length of therapy and the total dose rece... seizures in the past, or who have conditions that increase
their risk for seizures.
Call your doctor ...
Online H1N1 Management: FairChoice Helps Schools Respond to Infectious Disease on Campus
...ir message is getting out to students. FairChoice Health meets students where they are -- online. Our automated notification and tracking service will increase
student awareness of the risks of infectious disease and allow school administrators to focus on keeping students healthy," says Bernie Kluger, FairCh...
Is Your Hair Taking a Break?
...ons to prevent further hair loss.
Another common form of hair loss in both men and women, telogen effluvium, refers to an increase
in the number of hairs in the telogen, or rest, phase of the hair cycle, which typically lasts three months in the normal growth cycle. However, telog...
Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin
...ore receptive to the effects of estrogen than others, including the face. Dr. Parsons noted that estrogens benefit the skin in many ways, including an increase
in collagen content, water retention and elasticity. During pregnancy when estrogen levels are at their highest, women experience thicker hair and glo...
Diabetes Gene Raises Odds of Lower Birth Weight
...ion of insulin, an important fetal growth factor, during the prenatal period may cause a baby to be born smaller. Low birth weight is already known to increase
the risk of disease later in life, and the fetal insulin hypothesis proposes that the same gene that causes lower birth weight also increases the risk...
Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease
... risk for the disease. According to a census report on the prevalence of osteoporosis, the number of women suffering from the disease is predicted to increase
in Ohio by more than 22 percent by 2020. Despite this predicted increase, a national Harris Interactive survey commissioned by the Know My Bones Cou...
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
...ntravenously every six months for a period of two years.
The primary clinical endpoint for the trial was defined as a statistically significant increase
in the time to progression of the disease, as measured by the EDSS, in patients with HLA-DR2 and/or HLA-DR4 immune response genes. It is estimated tha...
S.C. Medical Home Pilot for Diabetes Enrolls 1,110
...iding discount vouchers for medications, offering discounted memberships to local gyms, and monitoring quality processes and outcomes measures to help increase
"Our case managers have been calling patients who are eligible for the pilot project, and the patients absolutely love it....
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
...enly distributed among the placebo and active dose group.
The mean increase
in blood pressure from baseline at 3 months, using a last observation carry...--------------------------- --- --- --- ---
in Blood Pressure (BP) 1 1% 7 5%
Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
...del for drug-evaluation studies using serial sampling. Generating rats with knockout mutations has been a major challenge, but the new technique will increase
the rat's usefulness in research pertaining to physiology, endocrinology, neurology, metabolism, parasitology, growth and development and cancer. Alo...
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
...loss of appetite, dark urine, or yellowing of the skin.
If you are of childbearing age, talk to your doctor before taking ACTOS, as it could increase
your chance of becoming pregnant. Talk to your doctor if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. When...
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
...west dose that effectively controls his/her symptoms.
ASMANEX may increase
the risk of some eye problems such as cataracts, glaucoma, and increased in...ting beta2-adrenergic agonists or LABAs. In patients with asthma, LABAs may increase
the chance of asthma related death. Therefore, FORADIL should only be used ...
July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
...mic movements, breathing techniques and focused intentions. Some approaches increase
energy while others are used to cleanse and heal the body.
Reiki...s do and may even by harmful to health. High-dose vitamin E supplements may increase
the risk of health failure or death.
Patients should talk to their car...